Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 77.6 kDa.
AF488
Excitation Wavelength: 488 nm
Emission Wavelength: 517 nm
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
5e5 of anti-GPC3 CAR-293 cells were stained with 100 μL of 3 μg/mL of Alexa Fluor 488-Labeled Human Glypican 3 Protein, His Tag (Cat. No. GP3-HA2H5) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor 488 signal was used to evaluate the binding activity (QC tested).
5e5 of PBMCs were stained with Alexa Fluor 488-Labeled Human Glypican 3 Protein, His Tag (Cat. No. GP3-HA2H5) and anti-CD3 antibody, washed and then analyzed with FACS. PE signal was used to evaluate the expression of CD3+ T cells in PBMCs, and Alexa Fluor 488 signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
ECT-204 | ECT-204; JWATM-204 | Phase 2 Clinical | Eureka Therapeutics Inc | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
GPC3-CAR-T cell therapy(Origincell Medical Technology) | Ori-CAR-001 | Phase 1 Clinical | Carcinoma, Hepatocellular | Details | |
Anti-GPC3-IRDye800CW | Clinical | Chinese Academy Of Sciences | Details | ||
CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
IM-83 CAR-T cell therapy | IM-83 | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Liver Neoplasms | Details |
TC-CAR-031 | TC-CAR-031; TC-CAR031 | Phase 1 Clinical | Zhejiang University | Carcinoma, Hepatocellular | Details |
GPC3 CAR-T therapy (Hrain Biotechnology) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Hepatocellular | Details | |
CAR-GPC3 T-cell (Drum Tower Hospital) | Phase 2 Clinical | Nanjing Drum Tower Hospital | Carcinoma, Hepatocellular | Details | |
Anti-GPC3 CAR T-cell therapy (Nanjing University) | Phase 1 Clinical | Nanjing University | Carcinoma, Hepatocellular | Details | |
GLYCAR T cell therapy (Baylor College of Medicine) | GLYCAR | Phase 1 Clinical | Baylor College Of Medicine | Liver Neoplasms; Rhabdomyosarcoma; Rhabdoid Tumor; Hepatoblastoma; Wilms Tumor; Liposarcoma; Endodermal Sinus Tumor; Carcinoma, Hepatocellular | Details |
GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
Codrituzumab | GC-33; RG-7686; RO-5137382 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
GPC-3298306 | GPC-3298306 | Phase 2 Clinical | National Cancer Center Of Japan | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
TAK-102 | TAK-102 | Phase 1 Clinical | Noile-Immune Biotech Inc | Solid tumours; Neoplasms | Details |
CT-0180 | CT-0180 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
GPC3-CAR-T cell therapy | CSG-GPC-3; CAR-GPC3 T-cell; GPC3-CAR/CSG-GPC3; anti-GPC-3 CAR T; KJgpc3-001; CT-011 | Phase 1 Clinical | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
B010-A | B010-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Carcinoma, Hepatocellular | Details |
CT-017 | CT-017 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Carcinoma, Hepatocellular | Details |
CT0181 | CT-0181 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Carcinoma, Hepatocellular | Details |
GPC3-targeted CAR-T (Peking University) | Phase 1 Clinical | Peking University | Carcinoma, Hepatocellular | Details | |
CAR (hYP7)-T cells (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Liver Neoplasms; Carcinoma, Hepatocellular | Details | |
Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd, Guangdong Zhaotai Invivo Biomedicine Co Ltd | Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details | |
BOXR-1030 | BOXR-1030 | Phase 2 Clinical | Unum Therapeutics Inc | Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Liposarcoma, Myxoid; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.